Access Investment Management LLC Lowers Stake in Integra LifeSciences Holdings Corporation $IART

Core Insights - Access Investment Management LLC reduced its stake in Integra LifeSciences Holdings Corporation by 14.6% during Q3, now holding 372,450 shares valued at approximately $5.34 million, representing 1.4% of its total holdings [2] - Several institutional investors have adjusted their positions in Integra LifeSciences, with GAMMA Investing LLC increasing its stake by 55.3% and Caitong International Asset Management Co. Ltd raising its stake by 205.9% [3] - Director Jeffrey A. Graves purchased 9,000 shares at an average price of $11.35, increasing his position by 28.05% [4] Institutional Holdings - Institutional investors collectively own 84.78% of Integra LifeSciences' stock [3] - Access Investment Management LLC's stake is now its 27th largest holding [2] Insider Transactions - Jeffrey A. Graves' recent purchase of shares indicates insider confidence, with his total holdings now valued at approximately $466,326.10 [4] Analyst Ratings and Price Targets - Analysts have mixed ratings on Integra LifeSciences, with two firms rating it as a Buy, two as Hold, and three as Sell [6] - Truist Financial lowered its price target from $15.00 to $13.00, while JPMorgan Chase & Co. increased its target from $12.00 to $13.00 [6] Financial Performance - Integra LifeSciences reported Q3 earnings of $0.54 per share, exceeding estimates by $0.11, with revenue of $402.06 million, slightly below expectations [8] - The company experienced a year-over-year revenue increase of 5.6% [8] Company Overview - Integra LifeSciences is a global medical technology company focused on neurosurgery, regenerative medicine, and reconstructive procedures, offering a range of surgical instruments and advanced wound care solutions [9][10]